Загрузка...
Bevacizumab for Advanced Breast Cancer: Hope, Hype, and Hundreds of Headlines
INTRODUCTION. On February 22, 2008, the Food and Drug Administration granted accelerated approval for the use of bevacizumab (Avastin) in metastatic breast cancer. Based on subsequent clinical trials, this approval was revoked on November 18, 2011. In this study, we categorize and analyze the newspa...
Сохранить в:
| Главные авторы: | , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
AlphaMed Press
2013
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3825300/ https://ncbi.nlm.nih.gov/pubmed/24072217 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0160 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|